Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Moodys
Medtronic
Colorcon
Johnson and Johnson

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,051,582

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,051,582
Title:Expression vectors comprising the mCMV IE2 promoter
Abstract: The invention relates to an expression vector comprising the promoter of the mCMV-IE2 gene, or a functional expression promoting fragment thereof, and/or an enhancer of the mCMV-IE2 gene, or a functional expression enhancing fragment thereof, wherein the expression vector does not contain any complete gene of the mCMV.
Inventor(s): Chatellard; Philippe (Lausanne, CH), Imhof; Markus (Chexbres, CH)
Assignee: MERCK SERONO SA (Coinsins, Vaud, CH)
Application Number:12/872,151
Patent Claims:1. An expression vector comprising a mCMV-IE2 promoter fragment consisting of nucleotides 1 to 39 of SEQ ID NO: 1 directly linked to a DNA sequence encoding a heterologous polypeptide.

2. The vector according to claim 1, wherein said vector further comprises a mCMV-IE2 enhancer comprising SEQ ID NO: 9.

3. The vector according to claim 2, wherein said mCMV-IE2 enhancer comprises SEQ ID NO: 10.

4. The vector according to claim 1, further comprising a second promoter different from said mCMV-IE2 promoter.

5. The vector according to claim 4, wherein the second promoter is the mCMV-IE1 promoter.

6. The vector according to claim 4, wherein the mCMV-IE2 promoter fragment and the second promoter are bi-directionally arranged.

7. The vector according to claim 4, further comprising one or more regulatory elements selected from a 5'UTR, an intron, a 3'UTR, a mRNA 3' end processing sequence, a polyadenylation site, or an internal ribosome entry sequence (IRES).

8. The vector according to claim 7, wherein the IRES is operably linked to a DNA sequence encoding at least one polycistronic mRNA.

9. The vector according to claim 7, further comprising one or more DNA element selected from an insulator, a boundary element, a locus control region (LCR), a matrix attachment region (MARs), an element for recombination or an element for cassette exchange.

10. A host cell transfected with the vector according to claim 1.

11. The host cell according to claim 10, wherein the host cell is a CHO cell.

12. A process for the production of a polypeptide comprising the step of transfecting a host cell according to claim 10 and culturing said host cell under conditions allowing expression of the polypeptide.

13. The process according to claim 12, wherein the transfection is a stable transfection.

14. The process according to claim 13, further comprising the step of isolating the polypeptide from the host cell or cell culture supernatant.

15. The process according to claim 12, further comprising the step of isolating the polypeptide from the host cell or cell culture supernatant.

16. The vector according to claim 1, wherein said expression vector further comprises a second promoter directly linked to a DNA sequence encoding a second polypeptide.

17. A host cell comprising an expression vector according to claim 16.

18. The vector according to claim 16, wherein the second promoter is different from said mCMV-IE2 promoter.

19. The vector according to claim 16, wherein the second promoter is the mCMV-IE1 promoter.

20. The vector according to claim 16, wherein the heterologous polypeptide or the second polypeptide is a marker protein.

21. The vector according to claim 20, wherein the marker protein is selected from an adenosine deaminase (ADA), an aminoglycoside phosphotransferase (neo), a dihydrofolate reductase (DHFR), a hygromycin-B-phosphotransferase (HPH), a thymidine kinase (tk), a xanthine-guanine phosphoribosyltransferase (gpt), a multiple drug resistance gene (MDR), an ornithine decarboxylase (ODC), carbamyl-P synthetase/aspartate transcarbamylase/dihydro-orotase, a puromycin acetyltransferase (PAC), a galactokinase, a human folate receptor, or a reduced folate carrier.

22. The vector according to claim 16, wherein the heterologous polypeptide or the second polypeptide is a reporter protein.

23. The vector according to claim 22, wherein the reporter protein is selected from a luciferase, a green fluorescent protein, an alkaline phosphatase, and a horseradish peroxidase or combinations thereof.

24. The vector according to claim 16, wherein the heterologous polypeptide and the second polypeptide are the same.

25. The vector according to claim 16, wherein the heterologous polypeptide and the second polypeptide are different.

26. The vector according to claim 25, wherein the heterologous polypeptide is a first subunit of a dimeric or a multimeric protein and the second polypeptide is a second subunit of a dimeric or a multimeric protein.

27. The vector according to claim 26, wherein the first and the second subunit comprise the alpha and the beta chain of a hormone selected from a human FSH, a human LH, a human TSH or a human CG.

28. The vector according to claim 26, wherein one subunit is a heavy chain and the other subunit is a light chain of an immunoglobulin.

Summary for Patent:   See Pricing

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03100617Mar 11, 2003

Details for Patent 9,051,582

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   See Pricing MERCK SERONO SA (Coinsins, Vaud, CH) 2023-03-11 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   See Pricing MERCK SERONO SA (Coinsins, Vaud, CH) 2023-03-11 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   See Pricing MERCK SERONO SA (Coinsins, Vaud, CH) 2023-03-11 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
McKesson
Dow
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.